Chiral Purity of Research Peptides: D-Amino Acids, Marfey's Reagent and Why Handedness Matters
Why D-amino acids appear in synthetic peptides, how racemization happens during synthesis and hydrolysis, and how Marfey's reagent and chiral methods measure the handedness of each residue.
A certificate of analysis usually reports mass and HPLC purity. Neither of those necessarily catches a subtler defect: an amino acid with the wrong handedness. Almost all the amino acids in natural peptides are the L form, but synthesis and even the testing process itself can convert some residues to the D form. A peptide with a D-residue in the wrong place has the same mass and may co-elute on a routine HPLC method, yet it is a different molecule. This article explains, for laboratory researchers, where D-amino acids come from, why they matter, and how chiral analysis measures them.
Chirality in one paragraph
Every amino acid except glycine has a central carbon bonded to four different groups, which means it can exist in two non-superimposable mirror-image forms, called enantiomers. By convention these are labelled L and D. Ribosomal protein synthesis in living cells uses almost exclusively L-amino acids, so "all-L" is the expected baseline for a peptide meant to match a natural sequence. A D-amino acid at a given position is a stereochemical error, not a different sequence: the connectivity is identical, only the three-dimensional arrangement at that one carbon is inverted.
Why handedness matters
Two molecules that differ only in the handedness of one residue can behave very differently:
- Shape and folding. A single D-residue can disrupt a helix or turn, changing how the peptide folds and how it presents to a binding partner.
- Protease resistance. D-amino acids are poorly recognised by many proteases, so a D-substitution can change a peptide's stability. This is sometimes exploited deliberately in designed peptides, but as an unintended impurity it is simply a different, uncharacterised species.
- Binding and activity. Because receptor and enzyme binding sites are themselves chiral, inverting one residue can reduce or abolish binding in the laboratory assays used to characterise a peptide. Our guide to receptor binding assays explains how such differences show up as changes in Kd or IC50.
The key point is that mass spectrometry cannot see this. Enantiomers and, in a single peptide, epimers at one residue have identical mass. A chiral-blind method will pass a partially racemized peptide. Detecting it requires a method that is itself sensitive to handedness.
Where D-amino acids come from: synthesis
The main source of unwanted D-residues in a synthetic peptide is racemization during the coupling step of solid-phase peptide synthesis (described in our SPPS overview). When an amino acid's carboxyl group is activated for coupling, it can cyclise transiently to a five-membered oxazolone intermediate. The proton on the alpha carbon of that oxazolone is relatively acidic and can be removed and re-added from either face, scrambling the stereochemistry. The mechanistic basis for this oxazolone pathway, and the distinction between enolization and oxazolone routes, was worked out in classic physical-organic studies by Goodman and McGahren in Tetrahedron in 1967 and by Kemp and Rebek in the Journal of the American Chemical Society in 1970.
Two practical consequences follow. First, some residues are more prone to racemization than others; histidine and cysteine are classic trouble cases. Second, the activation chemistry matters. The introduction of benzotriazole-based additives, beginning with Konig and Geiger's HOBt in Chemische Berichte in 1970 and later the more effective HOAt reported by Carpino in the Journal of the American Chemical Society in 1993, was driven largely by the need to suppress racemization during coupling. Newer additives such as Oxyma, reported by Subiros-Funosas and colleagues in Chemistry - A European Journal in 2009, were developed with the same goal and a better safety profile. A thorough treatment of the whole problem can be found in Benoiton's book Chemistry of Peptide Synthesis.
Where D-amino acids come from: the test itself
A subtle trap is that the analysis can create the very defect it is trying to measure. Determining amino acid composition or chiral purity usually requires hydrolysing the peptide into free amino acids, traditionally with hot 6 M hydrochloric acid for many hours (the method behind amino acid analysis). Those harsh acidic conditions can themselves racemize some residues.
Broberg and colleagues examined this directly in Amino Acids in 2021, describing in-peptide amino acid racemization through inter-residue oxazoline intermediates during acidic hydrolysis. The message for the analyst is that an apparent D-content can be partly an artefact of hydrolysis, so good chiral methods either use milder hydrolysis, run proper controls with all-L standards hydrolysed the same way, or correct for the known racemization background. A number reported without that control is hard to interpret.
Measuring handedness: Marfey's reagent
The most widely used approach for residue-level chiral analysis is Marfey's method. Marfey introduced the reagent, 1,5-difluoro-2,4-dinitrobenzene (FDNB-based, commonly abbreviated FDAA), in Carlsberg Research Communications in 1984. The idea is elegant: the reagent is itself a single enantiomer, so when it reacts with the amino acids released from a hydrolysed peptide, the L-amino acid and the D-amino acid form diastereomers rather than enantiomers.
Diastereomers, unlike enantiomers, have different physical properties and can be separated on an ordinary reversed-phase HPLC column without any special chiral stationary phase. The L-FDAA and D-FDAA derivatives of a given amino acid elute at different, reproducible times, so the ratio of the two peaks gives the D/L ratio for that residue. A comprehensive review of the method and its many variants was published by Bhushan and Bruckner in Amino Acids in 2004.
Other chiral methods
Marfey's reagent is not the only option:
- Chiral stationary phases. Columns bearing a chiral selector (for example ligand-exchange or macrocyclic-glycopeptide phases) can separate D and L amino acids directly, without derivatization to diastereomers.
- GC-based methods. Volatile derivatives of amino acids can be resolved on chiral GC columns, an approach long used in geochemistry and forensic dating.
- Intact chiral LC-MS. In favourable cases, epimeric peptides can be separated at the intact level on a chiral or specialised column, avoiding hydrolysis entirely and sidestepping the hydrolysis-racemization artefact.
Each has trade-offs in resolution, sample preparation and the number of residues it can report on, but all share the same principle: introduce or exploit a chiral environment so that mirror-image species stop being indistinguishable.
What this means for interpreting a COA
Routine COAs rarely report chiral purity, and for many stable sequences that is a reasonable default. But chirality is worth thinking about when:
- the sequence contains residues known to racemize readily, such as histidine or cysteine;
- the peptide was made by a route or at a scale where coupling conditions were not well controlled;
- a peptide shows the expected mass and HPLC purity but behaves unexpectedly in a binding or stability assay.
In those situations, Marfey analysis or a chiral LC method, run with proper all-L hydrolysis controls, is the tool that answers the question a mass spectrum cannot.
Summary
D-amino acids are a mass-silent, HPLC-often-silent class of impurity that arises mainly from racemization during peptide coupling, and can also be generated by the harsh hydrolysis used in testing. Because enantiomers and single-residue epimers share the same mass, detecting them requires a chiral method. Marfey's reagent, which turns enantiomers into separable diastereomers, has been the workhorse since 1984, complemented by chiral columns and GC methods. For any peptide where handedness could matter, a chiral purity check, run with the right controls, is the missing dimension that composition and mass alone cannot provide.
Related reading
- Solid-Phase Peptide Synthesis Explained
- Amino Acid Analysis for Research Peptides
- Peptide Sequencing by Tandem MS (MS/MS) Explained
- Receptor Binding Assays Explained
References
- Goodman M, McGahren WJ. Mechanistic studies of peptide oxazolone racemization. Tetrahedron. 1967;23(5):2031-2050. doi:10.1016/0040-4020(67)80037-1.
- Kemp DS, Rebek J. Peptide racemization mechanism. Kinetic isotope effect as a means of distinguishing enolization from oxazolone. Journal of the American Chemical Society. 1970;92(19):5792-5793. doi:10.1021/ja00722a071.
- Konig W, Geiger R. Eine neue Methode zur Synthese von Peptiden: Aktivierung der Carboxylgruppe mit Dicyclohexylcarbodiimid unter Zusatz von 1-Hydroxy-benzotriazolen. Chemische Berichte. 1970;103(3):788-798. doi:10.1002/cber.19701030319.
- Carpino LA. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. Journal of the American Chemical Society. 1993;115(10):4397-4398. doi:10.1021/ja00063a082.
- Subiros-Funosas R, Prohens R, Barbas R, El-Faham A, Albericio F. Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. Chemistry - A European Journal. 2009;15(37):9394-9403. doi:10.1002/chem.200900614.
- Marfey P. Determination of D-amino acids. II. Use of a bifunctional reagent, 1,5-difluoro-2,4-dinitrobenzene. Carlsberg Research Communications. 1984;49(6):591-596. doi:10.1007/bf02908688.
- Bhushan R, Bruckner H. Marfey's reagent for chiral amino acid analysis: a review. Amino Acids. 2004;27(3-4):231-247. doi:10.1007/s00726-004-0118-0.
- Broberg A, Nord C, Levenfors JJ, Bjerketorp J. In-peptide amino acid racemization via inter-residue oxazoline intermediates during acidic hydrolysis. Amino Acids. 2021;53(3):323-331. doi:10.1007/s00726-021-02951-7.
- Benoiton NL. Chemistry of Peptide Synthesis. CRC Press; 2005. doi:10.1201/9781420027693.
Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.